GlassScriptPhysician profile
Curt Paul Samlaska
NPI 1134289762
$100,827.11
in general payments reported to CMS, 2019-2025
42 companies · $11K in 2025
The $11K reported for 2025 was more than what 92% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $7,009 · 2021: $11K · 2022: $14K · 2023: $12K · 2024: $16K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $11K · Consulting Fee: $1,900 · Travel and Lodging: $1,437 · Education: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,850.00 |
| Food and Beverage | $10,591.29 |
| Consulting Fee | $1,900.00 |
| Travel and Lodging | $1,436.50 |
| Education | $375.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $81,463.78 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Amgen INC. | $3,841.03 | 2019-2025 | Otezla, Enbrel, Otezla |
| Ucb, INC. | $2,177.67 | 2020-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,861.82 | 2019-2025 | Tremfya, Stelara, Remicade |
| Novartis Pharmaceuticals Corporation | $1,603.85 | 2019-2025 | |
| Pfizer INC. | $1,335.45 | 2019-2025 | |
| Lilly USA, LLC | $1,053.23 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $820.28 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $794.75 | 2019-2025 | Ilumya, Absorica Ld, Winlevi |
| Genzyme Corporation | $594.05 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $583.95 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $544.30 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Leo Pharma INC. | $538.93 | 2019-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $509.96 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $415.48 | 2019-2024 | Siliq, Targretin, Duobrii |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curt Samlaska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.